Ophthalmology

Blue Sky Vision Welcomes Shane Rodgers as Vice President of Finance & Accounting

Retrieved on: 
Wednesday, October 23, 2019
Ophthalmology, Optometry

GRAND RAPIDS, Mich., Oct. 23, 2019 /PRNewswire-PRWeb/ -- Blue Sky Vision, the largest and fastest-growing eye care group in Michigan, is pleased to announce the appointment of Shane Rodgers as Vice President of Finance & Accounting.

Key Points: 
  • GRAND RAPIDS, Mich., Oct. 23, 2019 /PRNewswire-PRWeb/ -- Blue Sky Vision, the largest and fastest-growing eye care group in Michigan, is pleased to announce the appointment of Shane Rodgers as Vice President of Finance & Accounting.
  • Mr. Rodgers brings over 15 years of accounting and financial management leadership experience to his new role at Blue Sky Vision.
  • "Shane's proven track record of leading teams, driving growth, streamlining business operations, and increasing profit makes him a valuable addition to our team," said Dan Shoemaker, President of Blue Sky Vision.
  • To date, Blue Sky Vision partners include: Blue Sky Vision Three Rivers; Optometrists of Lansing; VisionCare Associates; EyeCare Associates of Haslett, Sussex Vision Centers; Vitreo-Retinal Associates; Michigan Optical; Shoreline Vision; Walker Surgical Center; Lakeshore Eye; Surgical Care Center of Michigan; and Grand Rapids Ophthalmology.

U.S. Food & Drug Administration Approves New Wet Age-Related Macular Degeneration Treatment

Retrieved on: 
Tuesday, October 22, 2019
Ophthalmology, Organ systems, Medicine, Breakthrough therapy, Angiogenesis inhibitors, Aflibercept, Bayer AG, Sanofi, RTT, Macular degeneration, Diabetic retinopathy, Retinopathy

This highly anticipated approval is the first major breakthrough in wet AMD treatment since the approval of Eylea (Aflibercept) in 2011.

Key Points: 
  • This highly anticipated approval is the first major breakthrough in wet AMD treatment since the approval of Eylea (Aflibercept) in 2011.
  • It is estimated that over 1.5 million people in the United States will have wet AMD by 2020 according to Novartis's recent release.
  • Until now, treatment for wet AMD consisted of drug injections (e.g., Eylea) into the eye as frequent as every month.
  • The clinic is currently engaged in over 15 protocols working to develop better therapies for people who suffer from age-related macular degeneration and diabetic retinopathy.

Robert Dempsey Joins iVeena Board of Directors

Retrieved on: 
Tuesday, October 22, 2019
Biotechnology, Health, Pharmaceutical, Optical, Clinical trials, Companies, Ophthalmology, Shire, Life sciences, Industries

iVeena Delivery Systems (iVeena) , a clinical stage biopharmaceutical company with developmental products in cataract and cornea, announces the appointment of Robert Dempsey , former Group Vice President and Head of the Global Ophthalmology Franchise at Shire/Takeda, to the iVeena Board of Directors.

Key Points: 
  • iVeena Delivery Systems (iVeena) , a clinical stage biopharmaceutical company with developmental products in cataract and cornea, announces the appointment of Robert Dempsey , former Group Vice President and Head of the Global Ophthalmology Franchise at Shire/Takeda, to the iVeena Board of Directors.
  • Robert Dempsey joined Shire in 2014 and was the Group Vice President and Head of the Global Ophthalmology Franchise.
  • I am excited to join the Board of iVeena, said Robert.
  • iVeena Delivery Systems, Inc. (iVeena) is a privately held, clinical stage biopharmaceutical company that develops innovative ophthalmology products in cataract and cornea.

New Hope for Patients With Vision Loss at SAVIR-Center for Vision Restoration

Retrieved on: 
Tuesday, October 22, 2019
Medicine, Clinical medicine, Health, Anxiety, Immune system, Psychosomatic medicine, Stress, Ophthalmology

Prof. Sabel has pioneered a holistic treatment approach that combines stress management, patient education, and vision recovery and restoration techniques at the SAVIR-Center for Vision Restoration in Germany.

Key Points: 
  • Prof. Sabel has pioneered a holistic treatment approach that combines stress management, patient education, and vision recovery and restoration techniques at the SAVIR-Center for Vision Restoration in Germany.
  • He notes that of the relatively few scientific reports in the field of psychosomatic ophthalmology available, even fewer explore the relationship of stress, vision loss, and vision restoration.
  • "The behavior and words of the treating physician can have far-reaching consequences for the prognosis of vision loss.
  • The SAVIR-Center for Vision Restoration in Germany has successfully applied above protocol on hundreds of patients in the last few years.

New Hope for Patients With Vision Loss at SAVIR-Center for Vision Restoration

Retrieved on: 
Tuesday, October 22, 2019
Medicine, Clinical medicine, Health, Anxiety, Immune system, Psychosomatic medicine, Stress, Ophthalmology

Prof. Sabel has pioneered a holistic treatment approach that combines stress management, patient education, and vision recovery and restoration techniques at the SAVIR-Center for Vision Restoration in Germany.

Key Points: 
  • Prof. Sabel has pioneered a holistic treatment approach that combines stress management, patient education, and vision recovery and restoration techniques at the SAVIR-Center for Vision Restoration in Germany.
  • He notes that of the relatively few scientific reports in the field of psychosomatic ophthalmology available, even fewer explore the relationship of stress, vision loss, and vision restoration.
  • "The behavior and words of the treating physician can have far-reaching consequences for the prognosis of vision loss.
  • The SAVIR-Center for Vision Restoration in Germany has successfully applied above protocol on hundreds of patients in the last few years.

Growth of Age-Related Macular Degeneration (AMD) Therapeutics Market to be Impacted by the Development of Gene Therapy for AMD | Technavio

Retrieved on: 
Monday, October 21, 2019
Health, Pharmaceutical, Ophthalmology, Macular degeneration, RTT, Senescence, Organ systems, Vision, Advanced Micro Devices, Stem cells, Geographic atrophy, Astellas Institute for Regenerative Medicine

Age-Related Macular Degeneration (AMD) Therapeutics Market 2019-2023: Geographic Landscape

Key Points: 
  • Age-Related Macular Degeneration (AMD) Therapeutics Market 2019-2023: Geographic Landscape
    Age-Related Macular Degeneration (AMD) Therapeutics Market 2019-2023: Type Landscape
    Register for a free trial today and gain instant access to 10,000+ market research reports.
  • Moreover, despite the high prevalence of AMD, no approved therapies are available in the market for the treatment of the condition.
  • Thus, the high prevalence coupled with the huge unmet medical need of dry AMD are expected to drive market growth during the forecast period.
  • Hence, the development of gene therapy is expected to be a positive trend for the global AMD therapeutics market.

SparingVision Nominated for the Prix Galien MedStart'up in the Category “Best Collaboration Dedicated to the Developing or Underserved Populations Worldwide”

Retrieved on: 
Monday, October 21, 2019
Biotechnology, Optical, Surgery, General Health, Health, Genetics, Clinical trials, Other Health, Ophthalmology, Blindness, Channelopathies, RTT, Retinitis pigmentosa, Retinal degeneration, Medical specialties, Organ systems, Retinitis, Foundation Fighting Blindness, Progressive retinal atrophy

Organized by the Fondation Galien and Business France, the Prix Galien MedStart'Up rewards the most promising start-ups in the healthcare sector, created by international partnerships between French and North American innovators.

Key Points: 
  • Organized by the Fondation Galien and Business France, the Prix Galien MedStart'Up rewards the most promising start-ups in the healthcare sector, created by international partnerships between French and North American innovators.
  • The Fighting Blindness Foundation, created in 1971, is one of the largest foundations in the United States for degenerative retinal diseases.
  • SparingVision has been selected for its treatment that fights against the most common retinitis pigmentosa of hereditary retinal degeneration.
  • SparingVision is developing SPVN06, a gene-independent drug candidate to treat retinitis pigmentosa, the most common inherited retinal degeneration.

Bausch + Lomb Introduces PreserVision® AREDS 2 Formula Minigel Eye Vitamins

Retrieved on: 
Monday, October 21, 2019
Age-Related Eye Disease Study, Ophthalmology, Vision, Medical specialties, National Eye Institute, Lomb, Macular degeneration, Bausch, Moran Eye Center, Emily Chew

launch of PreserVision AREDS 2 Formula minigel eye vitamins.

Key Points: 
  • launch of PreserVision AREDS 2 Formula minigel eye vitamins.
  • PreserVision AREDS 2 Formula minigel eye vitamins contain the exact nutrient formula recommended by the National Eye Institute (NEI) for people with moderate to advanced Age-related Macular Degeneration (AMD) following the landmark AREDS2 clinical study.
  • "Bausch + Lomb is committed to helping patients protect their vision," said Joe Gordon, U.S. president, Bausch + Lomb.
  • "Patients who take or are considering PreserVision AREDS 2 Formula minigel eye vitamins will now have a new, easier-to-swallow1 option."

CVP welcomes Cincinnati-based Apex Eye to its growing network of premier ophthalmology practices

Retrieved on: 
Friday, October 18, 2019
Ophthalmology, Ophthalmic, Optometry

CINCINNATI, Oct. 18, 2019 /PRNewswire/ --Apex Eye has joined CVP, the premier national ophthalmology management services organization in the nation.

Key Points: 
  • CINCINNATI, Oct. 18, 2019 /PRNewswire/ --Apex Eye has joined CVP, the premier national ophthalmology management services organization in the nation.
  • The new relationship aligns Apex Eye with the Cincinnati Eye Institute, a world-class center for ophthalmic care and the founding practice of CVP.
  • In turn, CVP will enable Apex Eye to drive growth in partnership with a network of leading ophthalmologists."
  • "Our alignment with CVP and the Cincinnati Eye Institute, equips Apex Eye to pursue visionary opportunities for eye care while defining a next-generation patient care experience."

Aequus Highlights Study Indicating Vistitan as the Most Effective Treatment for Glaucoma

Retrieved on: 
Friday, October 18, 2019
RTT, Prostaglandins, Blindness, Glaucoma, Bimatoprost, Organ systems, Ocular hypertension, Ophthalmology

This study adds to a growing body of evidence that Vistitan, the only bimatoprost 0.03% formulation currently marketed in Canada, is the most effective product available for treating glaucoma and is the cornerstone of our rapidly expanding ophthalmology franchise in Canada.

Key Points: 
  • This study adds to a growing body of evidence that Vistitan, the only bimatoprost 0.03% formulation currently marketed in Canada, is the most effective product available for treating glaucoma and is the cornerstone of our rapidly expanding ophthalmology franchise in Canada.
  • Bimatoprost 0.03% is a prostaglandin approved for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension.
  • Aequus began Canadian promotional activities for Vistitan in May 2016, on behalf of its partner.
  • Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products.